产品名称 | NebuSelect™ Recombinant Human ALK-1/Activin RL1, His-tag |
---|---|
目录号 | NBL-243117 |
别名 | ALK-1/Activin RL1; ACVRLK1; ORW2; ALK1; ALK-1; EC 2.7.11; HHT; HHT2; SKR3; TSR-I; ACVRL1 |
外观 | see COA |
分子量 | |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | P37023 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-243117-100ug | 100ug | Inquire | Inquire | |
NBL-243117-1mg | 1mg | Inquire | Inquire | |
NBL-243117-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human ALK-1/Activin RL1, His-tag
Catalog#:
NBL-243117
Description:
NebuSelect™ Recombinant Human ALK-1/Activin RL1, His-tag(Cat#NBL-243117) is expressed in HEK293 with His tag at the C-Terminus.It contains Asp22-Gln118.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 11.5 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Target Name:
ALK-1/Activin RL1; ACVRLK1; ORW2; ALK1; ALK-1; EC 2.7.11; HHT; HHT2; SKR3; TSR-I; ACVRL1
Target Information:
Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Amino Acid Sequence:
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.